1
|
Cambon A, Rebelle C, Bachelier R, Arnaud L, Robert S, Lagarde M, Muller R, Tellier E, Kara Y, Leroyer A, Farnarier C, Vallier L, Chareyre C, Retornaz K, Jurquet AL, Tran TA, Lacroix R, Dignat-George F, Kaplanski G. Macrophage IL-1β-positive microvesicles exhibit thrombo-inflammatory properties and are detectable in patients with active juvenile idiopathic arthritis. Front Immunol 2023; 14:1228122. [PMID: 38077384 PMCID: PMC10703381 DOI: 10.3389/fimmu.2023.1228122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 10/27/2023] [Indexed: 12/18/2023] Open
Abstract
Objective IL-1β is a leaderless cytokine with poorly known secretory mechanisms that is barely detectable in serum of patients, including those with an IL-1β-mediated disease such as systemic juvenile idiopathic arthritis (sJIA). Leukocyte microvesicles (MVs) may be a mechanism of IL-1β secretion. The first objective of our study was to characterize IL-1β-positive MVs obtained from macrophage cell culture supernatants and to investigate their biological functions in vitro and in vivo. The second objective was to detect circulating IL-1β-positive MVs in JIA patients. Methods MVs were purified by serial centrifugations from PBMCs, or THP-1 differentiated into macrophages, then stimulated with LPS ± ATP. MV content was analyzed for the presence of IL-1β, NLRP3 inflammasome, caspase-1, P2X7 receptor, and tissue factor (TF) using ELISA, Western blot, or flow cytometry. MV biological properties were studied in vitro by measuring VCAM-1, ICAM-1, and E-selectin expression after HUVEC co-culture and factor-Xa generation test was realized. In vivo, MVs' ability to recruit leukocytes in a murine model of peritonitis was evaluated. Plasmatic IL-1β-positive MVs were studied ex vivo in 10 active JIA patients using flow cytometry. Results THP-1-derived macrophages stimulated with LPS and ATP released MVs, which contained NLRP3, caspase-1, and the 33-kDa precursor and 17-kDa mature forms of IL-1β and bioactive TF. IL-1β-positive MVs expressed P2X7 receptor and released soluble IL-1β in response to ATP stimulation in vitro. In mice, MVs induced a leukocyte peritoneal infiltrate, which was reduced by treatment with the IL-1 receptor antagonist. Finally, IL-1β-positive MVs were detectable in plasma from 10 active JIA patients. Conclusion MVs shed from activated macrophages contain IL-1β, NLRP3 inflammasome components, and TF, and constitute thrombo-inflammatory vectors that can be detected in the plasma from active JIA patients.
Collapse
Affiliation(s)
- Audrey Cambon
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Service de Médecine interne et d’Infectiologie, Hôpital d’Instruction des Armées (HIA) Sainte-Anne, Service de Santé des Armées (SSA), Toulon, France
| | - Charlotte Rebelle
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Service de Pédiatrie, Assistance Publique des Hôpitaux de Marseille (AP-HM), Hôpital Nord, Marseille, France
| | - Richard Bachelier
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Laurent Arnaud
- Laboratoire d’Hématologie, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Timone, Marseille, France
| | - Stéphane Robert
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Marie Lagarde
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Romain Muller
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Service de Médecine interne et d’Immunologie clinique, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Conception, Marseille, France
| | - Edwige Tellier
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Yéter Kara
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Aurélie Leroyer
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Catherine Farnarier
- Laboratoire d’Immunologie, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Conception, Marseille, France
| | - Loris Vallier
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Corinne Chareyre
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
| | - Karine Retornaz
- Service de Pédiatrie, Assistance Publique des Hôpitaux de Marseille (AP-HM), Hôpital Nord, Marseille, France
| | - Anne-Laure Jurquet
- Service de Pédiatrie, Assistance Publique des Hôpitaux de Marseille (AP-HM), Hôpital Nord, Marseille, France
| | - Tu-Anh Tran
- Service de Pédiatrie, Centre Hospitalo-Universitaire (CHU) Nîmes, Hôpital Carémeau, Nîmes, France
| | - Romaric Lacroix
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Laboratoire d’Hématologie, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Timone, Marseille, France
| | - Françoise Dignat-George
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Laboratoire d’Hématologie, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Timone, Marseille, France
| | - Gilles Kaplanski
- Aix-Marseille University, Institut National de la Santé Et de la Recherche Médicale (INSERM), Institut National de la Recherche pour l’Agriculture et l’Environnement (INRAE), Centre de Recherche en CardioVasculaire et Nutrition (C2VN), Marseille, France
- Service de Médecine interne et d’Immunologie clinique, Assistance Publique des Hôpitaux de Marseille (AP-HM), La Conception, Marseille, France
| |
Collapse
|
2
|
Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Guen CGL, Angoulvant F, Belot A, Donzeau A, Aridi LE, Lety S, Leboucher B, Baur A, Jeusset L, Selegny M, Fedorczuk C, Lajus M, Bensaid P, Laoudi Y, Pons C, Robert AC, Beaucourt C, De Pontual L, Richard M, Goisque E, Iriart X, Brissaud O, Segretin P, Molimard J, Orecel MC, Benoit G, Bongiovanni L, Guerder M, Pouyau R, De Guillebon De Resnes JM, Mezgueldi E, Cour-Andlauer F, Horvat C, Poinsot P, Frachette C, Ouziel A, Gillet Y, Barrey C, Brouard J, Villedieu F, Ro V, Elanga N, Gajdos V, Basmaci R, Mutar H, Rouget S, Nattes E, Hau I, Biscardi S, Jurdi HE, Jung C, Semama D, Huet F, Zoccarato AM, Sarakbi M, Mortamet G, Bost-Bru C, Bassil J, Vinit C, Hentgen V, Leroux P, Bertrand V, Parrod C, Craiu I, Kone-Paut I, Durand P, Tissiere P, Claude C, Morelle G, Guiddir T, Borocco C, Delion F, Guillot C, Leteurtre S, Dubos F, Jouancastay M, Martinot A, Voeusler V, Languepin J, Garrec N, Demersay AC, Morand A, Bosdure E, Vanel N, Ughetto F, Michel F, Caujolle M, Blonde R, Nguyen J, Vignaud O, Masserot-Lureau C, Gouraud F, Araujo C, Ingrao T, Naji S, Sehaba M, Roche C, Carbasse A, Milesi C, Mazeghrane M, Haupt S, Schweitzer C, Romefort B, Launay E, Guen CGL, Ali A, Blot N, Tran A, Rancurel A, Afanetti M, Odorico S, Talmud D, Chosidow A, Romain AS, Grimprel E, Pouletty M, Gaschignard J, Corseri O, Faye A, Gaschignard J, Melki I, Ducrocq C, Benzoïd C, Lokmer J, Dauger S, Chomton M, Deho A, Lebourgeois F, Renolleau S, Lesage F, Moulin F, Dupic L, Pinhas Y, Debray A, Chalumeau M, Abadie V, Frange P, Cohen JF, Allali S, Curtis W, Belhadjer Z, Auriau J, Méot M, Houyel L, Bonnet D, Delacourt C, Meunier BB, Quartier P, Shaim Y, Baril L, Crommelynck S, Jacquot B, Blanc P, Maledon N, Robert B, Loeile C, Cazau C, Loron G, Gaga S, Vittot C, Nabhani LE, Buisson F, Prudent M, Flodrops H, Mokraoui F, Escoda S, Deschamps N, Bonnemains L, Mahi SL, Mertes C, Terzic J, Helms J, Idier C, Chenichene S, Ursulescu NM, Beaujour G, Hakim A, Miquel A, Rey A, Wiedermann A, Charbonneau A, Veauvy-Juven A, Ferry A, Mandelcwajg A, Rousseau A, Prenant A, Bourneuf AL, Filleron A, Robine A, Félix A, Parizel A, Labarre A, Cantais A, Ros B, Coulon B, Biot B, Dalichoux B, Fournier B, Cagnard B, Vanel B, Brossier D, Ménager B, Ozanne B, Marie-Jeanne C, Bergerot C, Chavy C, Guidon C, Fabre C, Galeotti C, Baker C, Ballot-Schmit C, Belleau C, Charasse C, Favel C, Toumi C, Ferrandiz C, Couturier C, Pouchoux C, Chomton-Cailliez M, Kevorkian-Verguet C, Brunet C, Manteau C, Mougey C, Santy C, Fitament C, Petriat C, Rebelle C, Charron C, Dartus M, Toulorge D, Guillou-Debuisson C, Bartebin D, Klein V, Broustal E, Desselas E, Marteau E, Bouvrot E, Delacroix E, Coinde E, Elnabhani L, Amouyal E, Chaillou E, Gabilly-Bernard E, Ruiz E, Thibault E, Robin E, Darrieux E, Blondel E, Socchi F, Cazassus F, Bajolle F, Lacin F, Madhi F, Zekre F, Guerin F, Boussicault G, Ginies H, Magloire G, Arnold G, Coulognon I, Sicard-Cras I, Kahn JE, Bordet J, Fausser JL, Baleine JF, Brice J, Gendras J, Pekin K, Norbert K, Karsenty C, Savary L, Martinat L, Lesniewski L, Charbonnier L, Alexandre L, Percheron L, Vincenti M, Selegny M, Lanzini M, Grisval M, Mercy M, Lampin ME, Desgranges M, Duperril M, Orcel MC, Audier M, Favier M, Carpentier M, Balcean M, Bonnet M, Jouret M, Delattre M, Levy M, Valensi M, Shum M, Dumortier M, Gelin M, Nemmouchi M, Williaume M, Sebaha M, Genetay-Stanescu N, Giroux N, Crassard N, Derridj N, Lachaume N, Werner O, Guilluy O, Richer O, Tirel O, Pauvert A, Casha P, Perez N, Gras P, Leger PL, Pinchou M, Mornand P, Largo P, Ibanez RC, Roulland C, Albarazi SH, Bichali S, Faton S, Schott A, Walser S, Guillaume S, Vincent S, Galene-Gromez S, Kozisek S, Maugard T, Blanc T, Navarro T, Lauvray T, Kovacs T, Launay V, Despert V, Lhostis V, Gall V, Micaelli X, Benadjaoud Y, Matoussi Z, Géniaux H, Facile A, Pietri T, Palassin P, Pinel S, Chouchana L, Callot D, Boulay C. Correction to “Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study”. Lancet Reg Health Eur 2022. [PMID: 35967266 PMCID: PMC9364716 DOI: 10.1016/j.lanepe.2022.100468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
3
|
Vinit C, Georgin-Lavialle S, Theodoropoulou A, Barbier C, Belot A, Mejbri M, Pillet P, Pachlopnik J, Poignant S, Rebelle C, Woerner A, Koné-Paut I, Hentgen V. Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review. Front Immunol 2021; 12:744780. [PMID: 34858402 PMCID: PMC8632237 DOI: 10.3389/fimmu.2021.744780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 10/19/2021] [Indexed: 12/02/2022] Open
Abstract
Background Interleukin (IL)-1 inhibitors represent the main treatment in patients with colchicine-resistant/intolerant familial Mediterranean fever (crFMF), mevalonate kinase deficiency (MKD), and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). However, the reasons for the use of IL-1 inhibitors in these diseases are still not completely clarified. Objective Identify real-life situations that led to initiating anakinra or canakinumab treatment in hereditary recurrent fevers (HRFs), combining data from an international registry and an up-to-date literature review. Patients and Methods Data were extracted from the JIRcohort, in which clinical information (demographic data, treatment, disease activity, and quality of life) on patients with FMF, MKD, and TRAPS was retrospectively collected. A literature search was conducted using Medline, EMBASE, and Cochrane databases. Results Complete data of 93 patients with HRF (53.8% FMF, 31.2% MKD, and 15.1% TRAPS) were analyzed. Data from both the registry and the literature review confirmed that the main reasons for use of IL-1 blockers were the following: failure of previous treatment (n = 57, 61.3% and n = 964, 75.3%, respectively), persistence of disease activity with frequent attacks (n = 44, 47.3% and n = 1,023, 79.9%) and/or uncontrolled inflammatory syndrome (n = 46, 49.5% and n = 398, 31.1%), severe disease complication or associated comorbidities (n = 38, 40.9% and n = 390, 30.4%), and worsening of patients' quality of life (n = 36, 38.7% and n = 100, 7,8%). No reasons were specified for 12 (16.4%) JIRcohort patients and 154 (12%) patients in the literature. Conclusion In the absence of standardized indications for IL-1 inhibitors in crFMF, MKD, and TRAPS, these results could serve as a basis for developing a treat-to-target strategy that would help clinicians codify the therapeutic escalation with IL-1 inhibitors.
Collapse
Affiliation(s)
- Caroline Vinit
- General Pediatrics, Versailles Hospital, Versailles, France
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Kremlin-Bicêtre, France
| | - Sophie Georgin-Lavialle
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Kremlin-Bicêtre, France
- Department of Internal Medicine, Sorbonne University, Tenon Hospital (APHP), Paris, France
| | - Aikaterini Theodoropoulou
- Pediatric Immuno-Rheumatology of Western Switzerland, Department Women-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland
- Pediatric Immuno-Rheumatology Department, University Hospital, Geneva, Switzerland
| | | | - Alexandre Belot
- Pediatric Nephrology Rheumatology and Dermatology, CHU Lyon, Lyon, France
- RAISE (Centre de référence des rhumatismes inflammatoires et maladies auto-immunes systémiques de l’enfant), Paris, France
| | - Manel Mejbri
- Pediatric Immuno-Rheumatology of Western Switzerland, Department Women-Mother-Child, Lausanne University Hospital, Lausanne, Switzerland
- Pediatric Immuno-Rheumatology Department, University Hospital, Geneva, Switzerland
| | - Pascal Pillet
- Pediatrics and Immunology, CHU Pellegrin, Bordeaux, France
| | | | | | | | - Andreas Woerner
- Pediatric Cardiology and Rheumatology, UKBB Hospital, Bâle, Switzerland
| | - Isabelle Koné-Paut
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Kremlin-Bicêtre, France
- Pediatric Rheumatology Department, Bicêtre Hospital, APHP, University of Paris Saclay, Kremlin Bicêtre, France
| | - Véronique Hentgen
- General Pediatrics, Versailles Hospital, Versailles, France
- CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Kremlin-Bicêtre, France
| |
Collapse
|